Freyja Healthcare, LLC announced today that the U.S. Food and Drug Administration has granted 510(k) clearance for VereSee™, its second-generation Mini Laparoscope with VisualEntry™ System. The clearance marks a significant step in the company's mission to enhance visualization during the earliest stages of minimally invasive surgery.
VereSee combines a miniature 2mm laparoscope with Freyja's VisualEntry System, allowing surgeons to visualize anatomy during the entry process—a critical step that traditionally occurs without direct vision. This new approach could address a fundamental challenge in laparoscopic surgery.
Mike MacKinnon, CEO of Freyja Healthcare, emphasized the importance of the clearance: "We believe surgeons should have the ability to see when it matters most. VereSee brings visualization to the very beginning of the procedure while also providing the functionality of a miniature laparoscope, which may enable surgeons to avoid opening an additional laparoscope for certain procedures."
Unlike conventional methods where initial abdominal access may be performed blindly, VereSee is designed to provide visualization during entry, not after. Once access is achieved, the same miniature laparoscope can be used for continued visualization, potentially eliminating the need for a separate scope.
The system pairs single-use entry components with reusable visualization technology, aiming to fit seamlessly into existing surgical workflows while supporting a practical economic model for healthcare providers. The FDA reviewed VereSee under the 510(k) premarket notification pathway and classified it as a Class II Endoscope and Accessories device.
Jon I. Einarsson, MD, founder of Freyja Healthcare, highlighted the broader implications: "VereSee represents more than a new method of laparoscopic entry. It is a miniature laparoscopic visualization platform that gives surgeons the opportunity to see anatomy from the moment of entry. We believe that has the potential to fundamentally change how surgeons think about access, while continuing to advance the miniaturization of laparoscopic visualization and scope functionality."
The clearance allows Freyja Healthcare to begin commercial introduction of VereSee, expanding access to hospitals, ambulatory surgical centers, and surgeons performing minimally invasive procedures. This development is particularly relevant given the growing emphasis on patient safety and procedural efficiency in surgery.
By enabling direct visualization during entry, VereSee could reduce the risk of complications such as inadvertent vessel or bowel injury, which are rare but serious. Additionally, the miniaturization of the scope may allow for less invasive procedures, potentially leading to smaller incisions, reduced pain, and faster recovery times for patients. For healthcare systems, the reusable visualization technology combined with single-use entry components may offer cost savings and inventory management benefits.
The FDA clearance of VereSee underscores a trend toward miniaturization and enhanced visualization in surgical devices, which could influence future innovations in the field. As Freyja Healthcare prepares to launch VereSee, the medical community will be watching to see how this technology impacts surgical outcomes and practice patterns.
